BioStock: Key steps taken by BiBBInstruments in 2021
Despite some turbulence for BiBBInstruments in the early parts of 2021, the Swedish medtech has been able to take some key steps in its clinical evaluation of the world’s first CE-marked electromechanical biopsy instrument – EndoDrill Model X. BioStock got in touch with CEO Fredrik Lindblad to get his thoughts on the challenges and most important milestones reached by the company in 2021 and his expectations for 2022.
Read the full interview with BiBBInstrument's CEO Fredrik Lindblad at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se